Cleo Diagnostics Revolutionises Ovarian Cancer Screening with Early Detection
Australia-based Cleo Diagnostics (ASX:COV) is poised to offer a groundbreaking solution for ovarian cancer screening through innovative blood tests that promise accurate and early cancer detection. In a recent interview, Cleo Diagnostics CEO Dr. Richard Allman discussed the company's path to revolutionise ovarian cancer screening. The insidious nature of ovarian cancer, which often goes undetected until it's too late, has necessitated a fresh approach to early diagnosis. Allman explained that the prototype test from Cleo Diagnostics exhibits a 95 percent sensitivity and specificity rate, and h...